SNAP-8 (10mg)

Research Overview

An octapeptide that competes with SNAP-25 for incorporation into the SNARE complex, reducing neuromuscular junction signaling. As an extended version of Argireline (Acetyl Hexapeptide-3), SNAP-8 offers enhanced competition for the SNARE complex binding site.

Origin: Extended analog of SNAP-25 competitor Argireline (Acetyl Hexapeptide-3)

Mechanism of Action

• SNARE complex disruption

• SNAP-25 competitive inhibition

• Reduced neurotransmitter vesicle fusion

• Topical muscle relaxation

• Expression line reduction

Primary Research Areas

• Expression wrinkle research

• Topical neuromodulation

• SNARE complex pharmacology

Key Published Findings

• Demonstrated SNARE complex disruption in vitro neurotransmission assays

• Reduced expression wrinkle depth by up to 63% in 28-day clinical study (topical)

• Enhanced activity compared to parent compound Argireline in competitive assays

Research Protocol

Commonly studied routes: Topical. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.

Storage

Room temperature in formulation

Important Notice

SNAP-8 (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.